These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2904510)

  • 1. A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines.
    Chan HS; Bradley G; Thorner P; Haddad G; Gallie BL; Ling V
    Lab Invest; 1988 Dec; 59(6):870-5. PubMed ID: 2904510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines.
    Bradley G; Naik M; Ling V
    Cancer Res; 1989 May; 49(10):2790-6. PubMed ID: 2565764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies.
    Grogan T; Dalton W; Rybski J; Spier C; Meltzer P; Richter L; Gleason M; Pindur J; Cline A; Scheper R
    Lab Invest; 1990 Dec; 63(6):815-24. PubMed ID: 1979362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma.
    Rutledge ML; Robey-Cafferty SS; Silva EG; Bruner JM
    Mod Pathol; 1990 May; 3(3):298-301. PubMed ID: 1972985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
    Haddad G; Thorner PS; Bradley G; Dalton WS; Ling V; Chan HS
    Lab Invest; 1994 Oct; 71(4):595-603. PubMed ID: 7967514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
    Meyers MB; Rittmann-Grauer L; O'Brien JP; Safa AR
    Cancer Res; 1989 Jun; 49(12):3209-14. PubMed ID: 2566379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
    Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
    Harker WG; Slade DL; Dalton WS; Meltzer PS; Trent JM
    Cancer Res; 1989 Aug; 49(16):4542-9. PubMed ID: 2568172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.
    Volm M; Bak M; Efferth T; Lathan B; Mattern J
    Anticancer Res; 1988; 8(4):531-5. PubMed ID: 2902821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
    Bodey B; Taylor CR; Siegel SE; Kaiser HE
    Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.
    Smith CD; Carmeli S; Moore RE; Patterson GM
    Cancer Res; 1993 Mar; 53(6):1343-7. PubMed ID: 8095179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of soluble P-glycoprotein in culture media and extracellular fluids.
    Chu TM; Lin TH; Kawinski E
    Biochem Biophys Res Commun; 1994 Aug; 203(1):506-12. PubMed ID: 7915520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer of adriamycin resistance by fusion of Mr 170,000 P-glycoprotein to the plasma membrane of sensitive cells.
    Belli JA; Zhang Y; Fritz P
    Cancer Res; 1990 Apr; 50(7):2191-7. PubMed ID: 1969329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD; Li M; Yuan Y; Mao N; Pan LY
    Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
    Slapak CA; Fracasso PM; Martell RL; Toppmeyer DL; Lecerf JM; Levy SB
    Cancer Res; 1994 Nov; 54(21):5607-13. PubMed ID: 7923205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.